

12TH SEPTEMBER 2017

BREATH SENSOR PARTNERSHIP WITH GREY INNOVATION COMMENCED

Respiri Limited is pleased to announce its partnership with leading technology commercialisation company Grey Innovation to produce its 2018 next generation breath sensor with a new creative design and superior ergonomics. This decision to work with Grey Innovation again evolved from broad ranging partnership discussions on the best pathways to commercialise AirSonea in China, Europe and other major international markets.

The importance of Grey committing to Respiri's final stage of commercialisation cannot be understated. Specifically, Grey's constructive working relationship with Respiri and intimate knowledge of the technology ensures the fastest completion and lowest execution risk for the upgrade of the breath sensor. It also enables Respiri & Grey Innovation to continue discussions on commercialisation options.

Chairman, Leon L'Huillier said, "We are delighted to get started on this final step to commercialisation with Grey Innovation. Their expertise contributed to the success of the research study conducted at the University of Chicago, providing significant updates to the first generation AirSonea for operation with the new software platform. During the research study Respiri management identified opportunities to improve the ergonomic and creative design".

Respiri's decision to fund and upgrade the 2018 version of the breath sensor, after receipt of the R&D rebate, places the company in a strong position to achieve the best outcome for shareholders in negotiating sales and distribution agreements.

Jenni Lightowers
Company Secretary

Ph: 1800 476 632

ABOUT RESPIRI

Respiri Limited (ASX:RSH) is a health technology company leading the way in the development of innovative devices and mobile health apps to improve the management of chronic and costly respiratory disorders such as asthma and COPD. Building on decades of experience in the research and development of cutting-edge clinical products for hospitals, the company has first-mover advantage in providing broad access to its proprietary acoustic based clinical solutions for remote monitoring with the development of a suite of over-the-counter connected devices.

Health authorities universally agree that mHealth solutions can transform asthma care and health conscious consumers are rapidly embracing patient self-management with the aid of smartphones, the growth engine for Respiri's flagship product, AirSonea®. With the addition of new products, including a connected device for nocturnal monitoring in development, Respiri has a captive market, globally, of parents and carers of young children who cannot perform lung function tests. Respiri products have been cleared for use by the US Food and Drug Administration, the European Union CE, the Australian TGA and the commencement of an approval process for Asian markets has begun.

Respiri is especially proud of its recent de-risking of milestones. The substantial achievements over the past 18 months place Respiri in a lower risk position and on the cusp of commercialisation compared to the vast majority of medical device and biotech companies.

ABOUT GREY INNOVATION

Grey Innovation is a commercialisation technology company based in Melbourne, partnering with universities and research institutes in Australia and Germany. Grey develops innovative technologies in Health, Security & Safety and Environmental fields, encompassing Internet of Things and Big Data. Its Medtech portfolio includes Dorsavi wearable movement sensor, Parkinson's KinetiGraph (PKG) and TALI training program for children with developmental disabilities along with projects in diabetes, paediatric lung function monitoring, heart failure monitoring, glaucoma implants, point of care diagnostics and the development of the bionic eye.